Bivalirudin, thrombin and platelets: clinical implications and future directions

Area of Science:

• Cardiovascular Biology
• Hematology
• Thrombosis Research

Background:

• Hemostasis understanding evolved from separate coagulation and platelet pathways to an integrated cell-based model.
• This new model emphasizes thrombin's central role in modulating coagulation and platelet activation.
• Thrombin is a critical activator of platelet aggregation and tissue-factor-induced thrombosis.

Purpose of the Study:

• To elucidate the updated cell-based model of hemostasis.
• To explain thrombin's pivotal role in thrombosis and platelet activation.
• To provide a mechanistic rationale for antithrombotic agent efficacy in acute coronary syndromes (ACS) and percutaneous coronary interventions (PCI).

Main Methods:

• Review of current literature on hemostasis, coagulation, and platelet biology.
• Analysis of thrombin's function as a platelet agonist and thrombosis activator.
• Correlation of in-vivo processes with clinical observations in ACS and PCI.

Main Results:

• Thrombin is a key effector and modulator of hemostasis, linking coagulation and platelet activation.
• Minute thrombin quantities amplify its own production, leading to rapid clot formation.
• Thrombin-mediated cell activation contributes to inflammatory processes in ACS.

Conclusions:

• The cell-based model provides a more accurate representation of in-vivo hemostasis.
• Understanding thrombin's role is crucial for developing effective antithrombotic strategies.
• Direct thrombin inhibitors like bivalirudin show advantages over heparin in PCI, supported by clinical trial data (e.g., REPLACE-2).